newsfilter
← Latest News
Business Wire·

Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer

Natera’s oncology portfolio featured in 25 ESMO abstracts including 9 oral presentations, with publications in Nature Medicine and ESMO Open Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision